Searchable abstracts of presentations at key conferences in endocrinology

ea0065p401 | Thyroid | SFEBES2019

Management of thyroid disease in pregnancy – a national survey

Watters Marianne , Lindsay Robert , Reynolds Rebecca , Stirling Angus , Carty David

Background: Thyroid disease in pregnancy can have a profound impact on both mother and fetus. Guidelines on diagnosis and management are lacking in the UK and there is significant variation between European and US guidelines. This survey aimed to gather data on current management by endocrinologists in Scotland.Methods: An online survey was created using Google Forms and emailed to endocrinology trainees and consultants in Scotland (April 2019). The surv...

ea0066oc8.5 | Oral Communications 8 | BSPED2019

The impact of Prader–Willi syndrome multidisciplinary clinic on growth parameters

Hu Kun , Krone Ruth , Follows Rebecca , Marks David , Barrett Timothy

Introduction: Prader–Willi Syndrome (PWS) is a rare genetic disorder due to loss of paternally inherited genes on chromosome 15q11-13. It is characterised by neonatal hypotonia, childhood hyperphagia and obesity, hypogonadism, cognitive and behavioural disabilities, and development of scoliosis. PWS multidisciplinary (MDT) clinics were introduced from 2004 at Birmingham Children’s Hospital, a tertiary paediatric centre. This enabled centralised coordination of growth...

ea0066p77 | Pituitary | BSPED2019

Observed effects of growth hormone doses on height in patients with Prader Willi Syndrome

Hu Kun , Krone Ruth , Follows Rebecca , Marks David , Barrett Timothy

Introduction: Prader–Willi Syndrome (PWS) is a rare genetic disorder due to loss of paternally inherited genes on chromosome 15q11-13. It is characterised by neonatal hypotonia, childhood obesity, hypogonadism, cognitive and behavioural disabilities, and development of scoliosis. We aimed to review the impact of growth hormone (GH) doses, scoliosis and IGF1 levels on height gain in children with PWS.Methods/design: Retrospective observational study ...

ea0064031 | A novel pathogenic mutation in neurofibromatosis type 1 | BES2019

A novel pathogenic mutation in neurofibromatosis type 1

Rebecca Fischler , Isabelle Vandernoot , Valerio Lucidi , Bernard Corvilain , Natacha Driessens

Introduction: Neurofibromatosis type 1 (NF1) is one of the most frequent genetic dominant syndrom in men with a prevalence of 1 in 2600 to 3000 individuals worldwide. NIH NF1 diagnostic criteria are driven by the most frequent manifestations of the disease (café au lait macules (CAL), neurofibromas, freckling, optic glioma, Lisch nodules and osseus lesions). There are many clinical manifestations of NF1 (neurological, cardiovascular, gastrointestinal, endocrine and orthop...

ea0048wd7 | Workshop D: Disorders of the adrenal gland | SFEEU2017

Cushing’s disease – the potential pitfalls of adrenal autonomy

Bolding Nathalie , Gorrigan Rebecca , Shaho Shang , Drake William

A 54-year-old female presented to her GP with a 9-year history of poorly controlled hypertension (requiring five drugs) and type 2 diabetes mellitus, associated with central weight gain, low mood and poor wound healing. On examination she had clinical evidence of glucocorticoid excess. Cushing’s syndrome was confirmed on low dose dexamethasone suppression testing (2+0 cortisol 857 nmol/l, 2+48 cortisol 346 nmol/l). Cushing’s day curve demonstrated loss of circadian r...

ea0044p170 | Neuroendocrinology and pituitary | SFEBES2016

Audit of adult GH replacement therapy in Derby

Yahia Seifeldin , Quah Edmond , Kinton Rebecca , Ali Hisham , Stanworth Roger

Introduction: In 2003, the UK National Institute for Clinical Excellence (NICE) established guidelines on the use of GH in adults. These guidelines state that recombinant GH should be used only for adults with a severe GH deficiency that severely affects their quality of life. To assess current practice in relation to these guidelines, a review of patients receiving GH treatment was performed. The aims were to assess if adults with GH deficiency met NICE criteria for GH therap...

ea0039ep58 | Diabetes | BSPED2015

Acute hyperglycaemia in cystic fibrosis related diabetes: the role of insulin pumps

Drew Samantha , Margetts Rebecca , Gordon Hannah , Peters Catherine

Cystic fibrosis related diabetes (CFRD) is the commonest co-morbidity in CF leading to increased mortality rates. The pathophysiology includes pancreatic fibrosis, reduction in α and ß-cell mass, delayed insulin secretion and variable insulin insensitivity. Insulin production can fluctuate with progression over time to an insulinopenic state. We report two cases of young people with CFRD with high insulin requirements, poor glycaemic control and improvement with the ...

ea0039ep90 | Miscellaneous/other | BSPED2015

Case of raised creatinine in a newborn with congenital hyperinsulinism: diazoxide induced acute kidney injury

Godinho Felvira , Lewin Rebecca , Park Julie , Losa Ignatius

Background: Congenital hyperinsulinism (CHI) is the result of unregulated insulin secretion from the pancreatic β-cells leading to severe hypoglycaemia.1 Diazoxide is effective in virtually all forms of CHI except in those due to recessive (and some dominant) inactivating mutations in ABCC8 and KCNJ11 and in patients with focal CHI.2 We report a case of CHI with acute kidney injury secondary to diazoxide.Case ...

ea0059p039 | Bone and calcium | SFEBES2018

Management of hypoparathyroidism against European guidelines: Experience of a large teaching hospital

Jamal Jameel , Scholes Amelia , Sagar Rebecca , Abbas Afroze

Background: Hypoparathyroidism is a rare endocrine disorder characterised by low serum calcium with inappropriately low parathyroid hormone (PTH) levels. Calcium and vitamin D analogues have traditionally been the mainstay of treatment. However, these treatments may cause complications and may not fully address the well-being of this patient group. This study evaluates the current management of hypoparathyroidism in a large UK teaching hospital compared against current Europea...

ea0059p040 | Bone and calcium | SFEBES2018

Symptom documentation in patients with primary hyperparathyroidism before and after the introduction of a symptom scoring questionnaire

Hamer Lucy , Miller Elsha Madgwick , Sagar Rebecca , Abbas Afroze

Background: Symptoms consistent with hypercalcaemia are an indication for surgery in patients with primary hyperparathyroidism (PHPT). However, symptoms can be subtle and may not be documented systematically. We analysed the documentation of symptoms in a large series of patients with PHPT, and the subsequent impact of introducing a symptom scoring questionnaire.Methods: A standardised proforma was used to retrospectively analyse symptom documentation by...